Abstract | BACKGROUND: METHODS: RESULTS: Of the 27 patients assigned to AEG35156 in combination with high-dose cytarabine and idarubicin, 3 died during reinduction chemotherapy, 5 achieved complete remission (CR), and 6 achieved CR with incomplete platelet count recovery (CRp), for an overall response rate of 41%. Of the 13 patients assigned to the control arm of the study, none died during reinduction, 6 achieved CR, and 3 achieved CRp, for an overall response rate of 69%. The differences in response rates between patients in the AEG35156 and control arms were not statistically different (P = 0.18 by the χ(2) test). CONCLUSIONS: The addition of AEG35156 to reinduction chemotherapy was well tolerated but did not improve rates of remission. Therefore alternative therapeutic strategies should be explored in patients with AML refractory to induction chemotherapy.
|
Authors | Aaron D Schimmer, Wolfgang Herr, Mathias Hänel, Gautham Borthakur, Arthur Frankel, Heinz-August Horst, Sonja Martin, Jeannine Kassis, Pierre Desjardins, Karen Seiter, Walter Fiedler, Richard Noppeney, Aristoteles Giagounidis, Christine Jacob, Jacques Jolivet, Martin S Tallman, Steffen Koschmieder |
Journal | Clinical lymphoma, myeloma & leukemia
(Clin Lymphoma Myeloma Leuk)
Vol. 11
Issue 5
Pg. 433-8
(Oct 2011)
ISSN: 2152-2669 [Electronic] United States |
PMID | 21729686
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2011 Elsevier Inc. All rights reserved. |
Chemical References |
- AEG 35156
- Oligonucleotides
- X-Linked Inhibitor of Apoptosis Protein
- XIAP protein, human
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Female
- Humans
- Leukemia, Myeloid, Acute
(drug therapy, genetics)
- Male
- Middle Aged
- Oligonucleotides
(administration & dosage)
- Remission Induction
- Treatment Outcome
- X-Linked Inhibitor of Apoptosis Protein
(antagonists & inhibitors, genetics)
- Young Adult
|